{
  "id": 7225054,
  "title": "Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer",
  "url": "https://urgent.news/2026/09/14/zidesamtinib-demonstrates-93-response-rate-in-ros1-positive-lung",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T01:50:04.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-zidesamtinib-response-ros1-positive-lung.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}